KCM
LAB icon

Kennedy Capital Management’s Standard BioTools LAB Stock Holding History

Kennedy Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-369,051
Closed -$4.55M – 708
2019
Q2 		$4.55M Buy
369,051
+355
+0.1% +$4.52K 0.11% 354
2019
Q1 		$4.9M Sell
368,696
-31,304
-8% -$330K 0.12% 333
2018
Q4 		$3.45M Buy
+400,000
New +$3.12M 0.09% 429

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Kennedy Capital Management's LAB Position: Q3 2019 in Review

Kennedy Capital Management sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 369,051 shares — an estimated $4.55M sold.

Kennedy Capital Management first reported a position in LAB in Q4 2018 and held it in 3 quarters. The position peaked at $4.9M in Q1 2019. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

  • Kennedy Capital Management reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
  • Kennedy Capital Management sold 369,051 Standard BioTools shares in Q3 2019, an estimated $4.55M.
  • Kennedy Capital Management first reported a position in Standard BioTools in Q4 2018 and held it in 3 quarters.
  • Kennedy Capital Management's Standard BioTools position peaked at $4.9M in Q1 2019.
  • 125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Kennedy Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.